[EN] 1,2,4-OXADIAZOLE DERIVATIVES AS LIVER X RECEPTOR AGONISTS<br/>[FR] DÉRIVÉS DE 1,2,4-OXADIAZOLE EN TANT QU'AGONISTES DU RÉCEPTEUR X DU FOIE
申请人:NOVARTIS AG
公开号:WO2021105857A1
公开(公告)日:2021-06-03
Provided herein are compounds and pharmaceutical compositions useful for treating meibomian gland dysfunction (MGD), comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) or a compound of Formula (I'), or pharmaceutical composition described herein.
Studies on Optically Active Amino Acids. XV. Studies on α-Alkyl-α-amino Acids. VIII. Absolute Configuration of Optically Active α-Methylserine and 2-Amino-2-methyl-3-butenoic Acid.
The absolute configuration of (+)-α-methylserine ((+)-IX) obtained from natural source, has been elucidated to be S-configuration by the chemical correlation with (+)-isovaline ((+)-VII), at the same time the absolute configuration of (+)-2-amino-2-methyl-3-butenoic acid ((+)-XI) has also been proved to be S-series. Chemical schemes employed were shown in Charts 1 and 2. Optically active hydantoins (V and VIII) used in the correlation were prepared by the direct resolution of racemic hydantoins with brucine. Preliminary examinations using racemic compounds were also reported.
通过与(+)-异戊氨酸((+)-VII)的化学关联,从天然来源获得的(+)-α-甲基丝氨酸((+)-IX)的绝对构型被阐明为 S 构型,同时(+)-2-氨基-2-甲基-3-丁烯酸((+)-XI)的绝对构型也被证明为 S 系列。采用的化学方案如图 1 和图 2 所示。相关研究中使用的光学活性海因(V 和 VIII)是通过外消旋海因与丁二酸的直接分解制备的。还报告了使用外消旋化合物进行的初步研究。
[EN] USE OF 1,2,4-OXADIAZOLE DERIVATIVES AS LIVER X RECEPTOR AGONISTS<br/>[FR] UTILISATION DE DÉRIVÉS DE 1,2,4-OXADIAZOLE EN TANT QU'AGONISTES DU RÉCEPTEUR X DU FOIE
申请人:NOVARTIS AG
公开号:WO2022249006A1
公开(公告)日:2022-12-01
Provided herein are compounds and pharmaceutical compositions useful for treating atopic dermatitis, contact dermatitis, chronic hand dermatitis, psoriasis, vitiligo, and alepecia areata, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) or a compound of Formula (I'), or pharmaceutical composition described herein. (I) (I')